Cancer Vaccines 15 - 16 September 2014, London

SMi present the 3rd Annual Cancer Vaccines Conference taking place in Central London on Monday 15th and Tuesday 16th September 2014.

This year's event will focus on the pre-clinical entities that are crucial when moving forward in clinical trials.   This will include, assessing antigen discovery and genome sequencing in addition to evaluating biomarkers and chimeric antigen receptors.

There is a growing demand for combination therapies and assessing clinical trial design, especially with failures in the clinic increasing, the question to be asked is how can we learn from this and move forward to ensure phase III developments and regulatory approval?

The agenda will focus on in vivo targeting of antigens to dendritic cells for therapeutic anti-cancer vaccines, reviewing preventive vaccine novel adjuvants programmes aswell as evaluating patient stratification.

Furthermore, it will enable a broad range of academics, small biotechs and large pharmaceutical companies to review analytical methods to enable reliability upon standardisation of assays. In addition to assessing the modulation of the tumour microenvironment within early stages of their research and development.

Cancer Vaccines 15 - 16 September 2014, London

SMi present the 3rd Annual Cancer Vaccines Conference taking place in Central London on Monday 15th and Tuesday 16th September 2014.

This year's event will focus on the pre-clinical entities that are crucial when moving forward in clinical trials.   This will include, assessing antigen discovery and genome sequencing in addition to evaluating biomarkers and chimeric antigen receptors.

There is a growing demand for combination therapies and assessing clinical trial design, especially with failures in the clinic increasing, the question to be asked is how can we learn from this and move forward to ensure phase III developments and regulatory approval?

The agenda will focus on in vivo targeting of antigens to dendritic cells for therapeutic anti-cancer vaccines, reviewing preventive vaccine novel adjuvants programmes aswell as evaluating patient stratification.

Furthermore, it will enable a broad range of academics, small biotechs and large pharmaceutical companies to review analytical methods to enable reliability upon standardisation of assays. In addition to assessing the modulation of the tumour microenvironment within early stages of their research and development.

Big DiP — Big Data in Pharma 2014 16 Sep 2014 -19 Sep 2014 Boston, United States

The 2nd annual Big DiP 2014 is packed with use cases and real results that cut through the big data hype and and shows what the future of of big data will look like.

Polymers in Drug Delivery 16 Sep 2014 - 17 Sep 2014 Philadelphia, United States

The event focuses on parenteral drug administration (PDA), i.e. non-oral routes of pharmaceutical delivery including pre-filled syringes, bags, tubes, inhalers, and implants that leach active ingredients.

Big DiP — Big Data in Pharma 2014 16 Sep 2014 -19 Sep 2014 Boston, United States

The 2nd annual Big DiP 2014 is packed with use cases and real results that cut through the big data hype and and shows what the future of of big data will look like.

Polymers in Drug Delivery 16 Sep 2014 - 17 Sep 2014 Philadelphia, United States

The event focuses on parenteral drug administration (PDA), i.e. non-oral routes of pharmaceutical delivery including pre-filled syringes, bags, tubes, inhalers, and implants that leach active ingredients.

Big DiP — Big Data in Pharma 2014 16 Sep 2014 -19 Sep 2014 Boston, United States

The 2nd annual Big DiP 2014 is packed with use cases and real results that cut through the big data hype and and shows what the future of of big data will look like.

Big DiP — Big Data in Pharma 2014 16 Sep 2014 -19 Sep 2014 Boston, United States

The 2nd annual Big DiP 2014 is packed with use cases and real results that cut through the big data hype and and shows what the future of of big data will look like.

Biosimilars and Biobetters 29 - 30 September 2014, London UK

Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs. As a result, the biosimilars manufacturing market is set to expand over the next decade and beyond as the drive to find cost-effective alternatives to biologics leads to the growing. In fact analysts predict that between 2013-2018, the global biosimilars market will grow at 27.58 %.

Returning for its fitfth year and following on from the major success of previous events, SMI are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Join us and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

Key topics include:

• Biosimilars, biobetters - the patients perspective
• The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry
• What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry
• Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars
• And much more!

BABE-2014 — 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit

29 Sep 2014 - 01 Oct 2014 Baltimore, United States

BABE-2014 is a scientific avenue for people from diversified Pharmaceutical backgrounds, Academic Institutions, Healthcare Institutes, Pharmaceutical Regulatory Agencies, Biotech and Clinical Research Organizations making the congress a desirable platform where participants can communicate and mutually get benefited by sharing experiences about their respective fields of interest, build collaborations with research organizations, acquire benefits from interactive workshops, promote innovative styles, trends and advancements of Bioavailability and Bioequivalence.

Biosimilars and Biobetters 29 - 30 September 2014, London UK

Impending patent expirations on blockbuster biologics and a volatile financial environment is causing payers to seek wider adoption of biosimilars in order to manage growing healthcare costs. As a result, the biosimilars manufacturing market is set to expand over the next decade and beyond as the drive to find cost-effective alternatives to biologics leads to the growing. In fact analysts predict that between 2013-2018, the global biosimilars market will grow at 27.58 %.

Returning for its fitfth year and following on from the major success of previous events, SMI are proud to present the 5th annual Biosimilars & Biobetters Conference, 29th-30th September, 2014, London. With an in-depth focus on the current and future landscape of the biosimilars market, this meeting will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Join us and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

Key topics include:

• Biosimilars, biobetters - the patients perspective
• The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry
• What is on the horizon? ... Reviewing the opportunities and challenges for the biopharmaceutical industry
• Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars
• And much more!

BABE-2014 — 5th World Congress on Bioavailabity and Bioequivalence: Pharmaceutical R&D Summit

29 Sep 2014 - 01 Oct 2014 Baltimore, United States

BABE-2014 is a scientific avenue for people from diversified Pharmaceutical backgrounds, Academic Institutions, Healthcare Institutes, Pharmaceutical Regulatory Agencies, Biotech and Clinical Research Organizations making the congress a desirable platform where participants can communicate and mutually get benefited by sharing experiences about their respective fields of interest, build collaborations with research organizations, acquire benefits from interactive workshops, promote innovative styles, trends and advancements of Bioavailability and Bioequivalence.